Lundbeck released a statement of the completion of the last set of the alcohol drinking reduction pill Nalmefene's massive phase three study. The results were similar as have been observed in previous studies. Wide variety of primary and secondary endpoints ensured some of them were hit straight on and even in those where statistical significance was not reached Nalmefene outperformed placebo according to the company.
Heavy drinking days and total alcohol consumption were reduced by more than 50% compared to pre-treatment baseline. Placebo effect was not given for comparisons sake in this case. The treatment effect of nalmefene was durable even after one year. Lundbeck and its partner Biotie are trading up in Nordic exchanges. Lundbeck plans to file MAA in Europe by years end.
No comments:
Post a Comment